Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

DOI record: { "DOI": "10.1371/journal.pone.0242184", "ISSN": [ "1932-6203" ], "URL": "http://dx.doi.org/10.1371/journal.pone.0242184", "abstract": "<jats:p>Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.</jats:p>", "author": [ { "affiliation": [], "family": "Camprubí", "given": "Daniel", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0003-4643-4456", "affiliation": [], "authenticated-orcid": true, "family": "Almuedo-Riera", "given": "Alex", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-7127-205X", "affiliation": [], "authenticated-orcid": true, "family": "Martí-Soler", "given": "Helena", "sequence": "additional" }, { "affiliation": [], "family": "Soriano", "given": "Alex", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-9519-6082", "affiliation": [], "authenticated-orcid": true, "family": "Hurtado", "given": "Juan Carlos", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-6246-8501", "affiliation": [], "authenticated-orcid": true, "family": "Subirà", "given": "Carme", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-7320-0965", "affiliation": [], "authenticated-orcid": true, "family": "Grau-Pujol", "given": "Berta", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-9054-1211", "affiliation": [], "authenticated-orcid": true, "family": "Krolewiecki", "given": "Alejandro", "sequence": "additional" }, { "affiliation": [], "family": "Muñoz", "given": "Jose", "sequence": "additional" } ], "container-title": "PLOS ONE", "container-title-short": "PLoS ONE", "content-domain": { "crossmark-restriction": false, "domain": [ "www.plosone.org" ] }, "created": { "date-parts": [ [ 2020, 11, 11 ] ], "date-time": "2020-11-11T18:40:53Z", "timestamp": 1605120053000 }, "deposited": { "date-parts": [ [ 2020, 11, 11 ] ], "date-time": "2020-11-11T18:41:12Z", "timestamp": 1605120072000 }, "editor": [ { "affiliation": [], "family": "Dorlo", "given": "Thomas P.C.", "sequence": "first" } ], "indexed": { "date-parts": [ [ 2024, 3, 8 ] ], "date-time": "2024-03-08T12:24:07Z", "timestamp": 1709900647277 }, "is-referenced-by-count": 43, "issue": "11", "issued": { "date-parts": [ [ 2020, 11, 11 ] ] }, "journal-issue": { "issue": "11", "published-online": { "date-parts": [ [ 2020, 11, 11 ] ] } }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 11, 11 ] ], "date-time": "2020-11-11T00:00:00Z", "timestamp": 1605052800000 } } ], "link": [ { "URL": "https://dx.plos.org/10.1371/journal.pone.0242184", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "340", "original-title": [], "page": "e0242184", "prefix": "10.1371", "published": { "date-parts": [ [ 2020, 11, 11 ] ] }, "published-online": { "date-parts": [ [ 2020, 11, 11 ] ] }, "publisher": "Public Library of Science (PLoS)", "reference": [ { "author": "The RECOVERY Collaborative Group", "journal-title": "New Engl J Med", "key": "pone.0242184.ref001" }, { "article-title": "Remdesivir for the treatment of Covid-19—preliminary report", "author": "JH Beigel", "journal-title": "New Engl J Med", "key": "pone.0242184.ref002", "year": "2020" }, { "article-title": "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review", "author": "JM Sanders", "journal-title": "JAMA", "key": "pone.0242184.ref003", "year": "2020" }, { "article-title": "The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro", "author": "L Caly", "first-page": "104787", "journal-title": "Antiviral Res.", "key": "pone.0242184.ref004", "volume": "2020" }, { "article-title": "Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency", "author": "C Chaccour", "first-page": "1", "journal-title": "Am J Trop Med Hyg", "key": "pone.0242184.ref005", "year": "2020" }, { "DOI": "10.4269/ajtmh.16-0923", "article-title": "Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries", "author": "A Requena-Méndez", "doi-asserted-by": "crossref", "first-page": "645", "issue": "3", "journal-title": "Am J Trop Med Hyg.", "key": "pone.0242184.ref006", "volume": "97", "year": "2017" }, { "DOI": "10.1093/jac/dkz524", "article-title": "Safety of high-dose ivermectin: a systematic review and meta-analysis", "author": "M Navarro", "doi-asserted-by": "crossref", "first-page": "827", "issue": "4", "journal-title": "J Antimicrob Chemother.", "key": "pone.0242184.ref007", "volume": "75", "year": "2020" }, { "DOI": "10.1371/journal.pntd.0006020", "article-title": "Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers", "author": "J Muñoz", "doi-asserted-by": "crossref", "first-page": "e0006020", "issue": "1", "journal-title": "PLoS Negl Trop Dis", "key": "pone.0242184.ref008", "volume": "12", "year": "2018" }, { "DOI": "10.1093/cid/ciy246", "article-title": "Efficacy and safety of ivermectin against Trichuris trichiura in preschool-aged and school-aged children: a randomized controlled dose-finding trial", "author": "D Wimmersberger", "doi-asserted-by": "crossref", "first-page": "1247", "journal-title": "Clin Infect Dis", "key": "pone.0242184.ref009", "volume": "67", "year": "2018" }, { "DOI": "10.1016/S1473-3099(19)30289-0", "article-title": "Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial", "author": "D Buonfrate", "doi-asserted-by": "crossref", "first-page": "1181", "issue": "11", "journal-title": "Lancet Infect Dis", "key": "pone.0242184.ref010", "volume": "19", "year": "2019" }, { "DOI": "10.1093/cid/ciy1063", "article-title": "Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial)", "author": "MR Smit", "doi-asserted-by": "crossref", "first-page": "1112", "issue": "7", "journal-title": "Clin Infect Dis.", "key": "pone.0242184.ref011", "volume": "69", "year": "2019" }, { "DOI": "10.1016/j.trstmh.2003.10.018", "article-title": "Adverse systemic reactions to treatment of onchocerciasiswith ivermectin at normal and high doses given annually or three-monthly", "author": "J Kamgno", "doi-asserted-by": "crossref", "first-page": "496", "journal-title": "Trans R Soc TropMed Hyg", "key": "pone.0242184.ref012", "volume": "98", "year": "2004" }, { "DOI": "10.1177/009127002401382731", "article-title": "Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects", "author": "CA Guzzo", "doi-asserted-by": "crossref", "first-page": "1122", "journal-title": "J Clin Pharmacol", "key": "pone.0242184.ref013", "volume": "42", "year": "2002" }, { "article-title": "Ivermectin as a potential COVID-19 treatment from a pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens", "author": "G Momekov", "first-page": "1, 469", "journal-title": "Biotechnology & Biotechnological Equipment", "key": "pone.0242184.ref014", "volume": "34" } ], "reference-count": 14, "references-count": 14, "relation": {}, "resource": { "primary": { "URL": "https://dx.plos.org/10.1371/journal.pone.0242184" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Multidisciplinary" ], "subtitle": [], "title": "Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1371/journal.pone.corrections_policy", "volume": "15" }